The MYCN gene gives cells instructions that help control growth and development, especially before birth and in early childhood. This gene plays an important role in the developing nervous system. If the MYCN gene is not working properly, an inherited variant can affect body and brain development, while extra copies of the gene can cause some cells to grow too much and may lead to neuroblastoma, a cancer that starts in immature nerve cells.
What is a gene?
Genes are stretches of DNA that hold instructions cells use to make molecules or manage processes throughout the body. Some genes provide the code for proteins, which do much of the cell’s work. Others mainly regulate when certain processes happen, where they happen, and how active they are. Taken together, genes affect how the body develops and functions, and they can also influence how you respond to food, stress, and medications. For a deeper look at this topic, see the LearnHub.
Overview
MYCNGene function
What if the gene works
The MYCN gene helps switch other genes on and off so cells can grow, divide, and mature, especially during early development. It is most active in developing tissues, including the nervous system.
Risk
What if the gene does not work
More disruptive variants in the MYCN gene can cause Feingold syndrome, with small head size, short stature, and hand or foot differences; milder variants may cause fewer features. Extra MYCN activity can also drive cancers such as neuroblastoma.
Treatment
What does that mean for your treatment
No MYCN-specific treatment or management approach is currently established for inherited pathogenic or loss-of-function variants in the MYCN gene. In cancer care, MYCN amplification (extra copies of the gene) is a well-established biomarker in neuroblastoma that helps guide risk grouping and treatment intensity, while direct MYCN-targeted drugs are still under study.
Conditions associated with MYCN
Gene function
What if the gene works
Your body uses the MYCN gene to help cells grow, divide, and mature at the right pace, especially before birth and in early life. It acts like a control switch for many other genes. This helps explain how the MYCN gene supports normal cell growth and development.
The MYCN gene helps control when many other genes are turned on or off. This gives cells clear instructions for growth, energy use, and building the parts they need.
Its protein supports the steps cells use to make proteins, copy key materials, and increase in size. That steady buildup helps a cell get ready for normal division.
MYCN helps coordinate the cell cycle, which is the ordered process cells use to divide. This keeps growth organized as tissues expand.
During fetal development, this gene is especially active in fast growing tissues, including the developing nervous system. It helps immature cells multiply and mature in a controlled way.
What is a variant?
A genetic variant is a small difference in the DNA sequence within a gene. These differences are common and help account for normal human diversity, such as variation in appearance, metabolism, or the way the body responds to environmental influences. Many variants do not have any noticeable effect and are simply part of natural genetic variation. In some cases, though, a variant can change how a gene functions more substantially and may contribute to or cause a genetic condition.
Genetic variants
What if the gene does not work
Some variants in the MYCN gene shorten the protein so it works poorly or not at all, while others change the DNA-binding region and only partly reduce its activity. This is how variants influence the MYCN gene's function at the cellular level: they can weaken the protein's stability, its ability to bind DNA, or its control over other genes. Milder variants may leave some function intact, but more severe variants can cause a clearer MYCN-related condition or broader features earlier in life.
How variants are linked to conditions
Information on MYCN gene variants linked to conditions most often centers on Feingold syndrome type 1, which is caused by pathogenic variants in the MYCN gene and can include short stature, small fingers or toes, and learning or developmental differences. Extra copies of the MYCN gene found only in tumor cells are also strongly associated with neuroblastoma and can point to a higher chance of a more aggressive cancer course. These tumor changes are different from inheriting a MYCN variant.
A variant is not necessarily a diagnosis
Genetic variants are a routine feature of human biology and occur widely across the population. Most do not directly affect health and instead reflect normal human variation. For many genes, having a variant connected with a condition points to a potential association, not a certain diagnosis, particularly when several genes and environmental influences also play a part. In some situations, though, one well characterized variant in a particular gene is enough to confirm the diagnosis.
Are there things that can increase or change my risk?
There is not yet broadly confirmed evidence on specific lifestyle or environmental factors that clearly increase or reduce health risk related to the MYCN gene. For many living with a MYCN change, risk is shaped mainly by the specific variant itself and family history rather than day-to-day habits. Anyone concerned about personal or family risk should speak with a doctor or genetic counselor.
Inheritance of MYCN variants
Variants in the MYCN gene that cause Feingold syndrome type 1 are inherited in an autosomal dominant pattern. This means a parent with the variant can pass it to each child with a 50% chance, so the way MYCN gene variants are inherited is usually from one affected parent to a son or daughter. Some people have a new, de novo variant in the MYCN gene, which means it was not inherited from either parent.
What does my MYCN result mean for my family?
For inherited MYCN-related conditions such as Feingold syndrome, the pattern is usually dominant, so close relatives like a parent, brother, sister, or child may also carry the same gene change and may want to learn whether it runs in the family. A child of someone with a disease-causing MYCN variant has a 1 in 2, or 50%, chance of inheriting it. Some cases happen for the first time in one person, so a parent is not always the source.
Genetic information
Genetic testing
How you find out about variants
MYCN genetic testing looks for changes in the MYCN gene using a blood, saliva, or tumor sample, depending on why testing is being done. A lab reads the gene or checks how many copies are present, which can help confirm a diagnosis, clarify inherited risk in some settings, or guide care when a tumor is being evaluated.
When should I consider getting a genetic test?
Consider MYCN testing if a child or family member has signs of Feingold syndrome, such as a smaller head size, differences in the fingers or toes, learning problems, or certain digestive tract birth changes. MYCN testing may also be part of tumor testing in neuroblastoma, because changes in this gene can help guide care.
A genetic result is only one part of your health story
Genetic results can provide meaningful insight, but how much they reveal varies by the condition and the type of variant involved. Over time, many factors, including lifestyle, environment, age, and medical history, also shape how the body functions. For some conditions, especially those influenced by many genes, genetic information provides context rather than certainty and is best understood together with other parts of care. In other situations, a genetic result may offer a clear answer. In areas such as medication response, these results can also help put individual experiences into perspective.
Pharmacogenetics
How variants shape your response to medicine
Genetic variation can affect how people respond to medicines. Small differences in genes can change how the body breaks down a drug, moves it through the bloodstream, or responds to it at its target. This helps explain why the same medication may work well for one person, work less well for another, or cause more side effects in someone who is more sensitive to it.
What is Pharmacogenetics?
Pharmacogenetics examines how differences in genes affect the way people respond to medications. It studies patterns between genes and drugs to understand more clearly why the same treatment can work differently from one person to another. For many medicines, genes influence both how strongly a drug works and how the body handles it. This information can support treatment decisions that are better informed and more individualized. More detail on this topic is available in the LearnHub.
Drugs influenced by the MYCN gene
When should I seek medical advice?
There is not yet a broadly confirmed role for this gene in guiding routine medication choices, so questions about side effects, treatment changes, or new medicines are best discussed with your doctor. MYCN has been studied mainly in cancer care, especially neuroblastoma, as a marker of tumor behavior rather than a standard guide to how medicines should be used.
History
MYCN entered medical genetics through childhood cancer research in the early 1980s, when scientists studying neuroblastoma found that some tumors carried many extra copies of this gene. This was a landmark moment because those extra copies were linked to a more aggressive course, helping doctors sort tumors into different risk groups. First described in the scientific literature as part of early genetics, MYCN soon became one of the clearest examples of how a gene change in a tumor can shape prognosis. Building on this early work, scientists uncovered more about the gene in other cancers and in rare inherited conditions affecting development. Over time, MYCN helped connect laboratory cancer research with everyday clinical decision-making. Its history remains closely tied to major advances in pediatric oncology.